Patients will be randomly divided into 2 groups, one of them treated with a known formulation of Latanoprost 0.005% (GAAP Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with PRO-067 ophthalmic solution. Patients will receive 1 drop QD into the lower conjunctival sac of either formulations and were examined at days: 1, 15, 30, 45 ad 61 after initiation of treatment. A phone call security at day 75 will be performed.